Bubble or no bubble, this is the best stock for AI exposure: analyst
TuHURA Biosciences, Inc. (NASDAQ:HURA) announced that its shelf registration statement on Form S-3, initially filed with the Securities and Exchange Commission on November 3, 2025, became effective on Friday in accordance with Section 8(a) of the Securities Act of 1933. The company is incorporated in Nevada and is based in Tampa, Florida.
As previously disclosed, TuHURA Biosciences completed a private placement with investors on June 2, 2025, involving shares of its common stock and warrants to purchase common stock. In connection with this transaction, the company registered the offer and sale of up to 9,321,545 shares of common stock, which includes up to 4,570,629 shares of common stock and 4,750,916 shares issuable upon exercise of warrants. These shares were initially registered under a resale registration statement on Form S-1, declared effective by the SEC on September 26, 2025.
With the effectiveness of the new shelf registration statement, the offering of the same shares by the selling securityholders named in the previous resale registration statement will now be made from time to time under the shelf registration statement. The prior resale registration statement is deemed terminated as of the effective date of the shelf registration statement, in accordance with Section 415(a)(6) of the Securities Act.
This information is based on a press release statement included in a recent SEC filing.
In other recent news, TuHURA Biosciences released updated unaudited pro forma financial statements following significant mergers. The company completed the acquisition of Kineta, Inc. on June 30, 2025, and a reverse merger with Kintara Therapeutics, Inc. on October 18, 2024. These financial statements, filed with the Securities and Exchange Commission, reflect the combined operations as if the mergers had occurred on January 1, 2024. Additionally, TuHURA Biosciences announced that its research on the Delta Opioid Receptor (DOR) in cancer immunotherapy has been accepted for presentation at the American Society of Hematology Annual Meeting. This research, which will be featured in an oral presentation, demonstrates that DOR is expressed on tumor-associated myeloid-derived suppressor cells and macrophages. These findings are significant as they provide insights into the immune response to cancer. The presentation is scheduled for the ASH Annual Meeting in December 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.